Clinical Trial Update: RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp. [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial comparing meropenem to piperacillin-tazobactam for definitive treatment of bloodstream infections caused by ceftriaxone-non-susceptib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bloodstream Infection
• Escherichia Coli Infection
• Klebsiella Infection

Drugs mentioned

• Meropenem (Meropenem)
• Zosyn (Piperacillin/tazobactam)

Snippet

Sponsor: The University of Queensland | Conditions: Bloodstream Infections | Phase 4 | Status: TERMINATED